Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Drug pipeline: 4Q18 | Nature Biotechnology
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
2017 Annual Report: Top 10 Pipelines – PharmaLive
Fresh from the biotech pipeline—2012 | Nature Biotechnology
Producing Quality Products | Teva Pharmaceuticals
Teva Pharmaceuticals Acquisition – PL Developments
EX-99.1
Teva expects FDA preapproval inspection of troubled Celltrion plant this year | FiercePharma
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | FiercePharma
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
Teva starts M&A push with $3.5bn Auspex buy - PMLiVE
EX-99.1
Refreshing the biologic pipeline 2020 | Nature Biotechnology
Sosei see Teva pipeline cull as an opportunity -
A Look at Teva's Generic Drugs Research Pipeline
EX-99.1
Celltrion FDA warning causes headache for Teva's biologics ambition
SymBio Pharmaceuticals : Pipeline : Treakisym® SyB L-0501
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com
Anything but Generic: A map for Selling to Teva Pharmaceuticals
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CCBS56SBRRKUDM7JEVVE3UOQEE.jpg "Teva halts output at U.S. drug plant after FDA flags concerns | Reuters")
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva-Takeda joint venture divests certain assets in Japan to Nichi-Iko - Pharmaceutical Technology
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
